¿ AnorMED Inc., of Vancouver, British Columbia, acquired a database of compounds from British Biotech Pharmaceuticals Ltd. for C$450,000 (US$293,330). The compounds have shown activity against a select group of chemokine receptors. AnorMED will get exclusive rights to information generated from the screening of the more than 60,000 compounds.
¿ Athersys Inc., of Cleveland, said the May issue of Nature Biotechnology contains a paper describing Athersys¿ Random Activation of Gene Expression technology. The paper illustrates how RAGE can be used to produce proteins encoded by genes associated with particular biological characteristics. The RAGE platform is a gene expression system that can produce protein from genes in the human genome without requiring the cloning of individual genes or use of cDNA libraries.
¿ Cytochroma Inc., of Kingston, Ontario, entered a collaboration with Molecular Mining Corp., also of Kingston, to search for genes to enhance Cytochroma¿s library of validated molecular targets for drug discovery. Financial details were unavailable.
¿ Delsys Pharmaceutical Corp., of Monmouth Junction, N.J., appointed its president, David King, CEO of the company, effective at the end of June. King was CEO of Principia Pharmaceutical Corp., of Norristown, Pa., and became president of Delsys in January after Principia was acquired by Human Genome Sciences Inc., of Rockville, Md.
¿ Dendreon Corp., of Seattle, discovered a gene expressed in several cancers but not significantly expressed in normal tissue. The study describes the identification and cloning of the gene, trp-p8, and the display of this gene on a number of cancers including those of the lung, breast, colon and prostate. The discovery was reported in the May edition of Cancer Research.
¿ Genaera Corp., of Plymouth Meeting, Pa., said its second aminosterol development compound, produlestan, showed appetite suppressant properties in animal models. The results of the study were published in the May issue of International Journal of Obesity. Produlestan was shown to control food intake of genetically obese and normal mice and was capable of reducing fat stores.
¿ Genomica Corp., of Boulder, Colo., signed an agreement with Celera Genomics Inc., of Rockville, Md., for Genomica to create a ¿Celera Edition¿ of its Discovery Manager genetic analysis software suite to integrate with the SNP Reference Database module of the Celera Discovery System. Financial terms were not disclosed.
¿ Lilly ICOS LLC, of Bothell, Wash., said results to be presented for the first time at the 96th Annual Meeting of the American Urological Association in Anaheim, Calif., indicate that Cialis, a PDE5 inhibitor, improved men¿s ability to achieve erections 24 hours after taking the drug. Men receiving Cialis were significantly more successful at achieving erections than men in the placebo group as measured by a RigiScan device after exposure to visual sexual stimulation.
¿ Myriad Genetics Inc., of Salt Lake City, began preclinical testing of MPC-1203, its proprietary protein drug for the treatment of acute thrombotic events due to inflammation following major trauma, orthopedic or open heart surgery. MPC-1203 also is designed for the prevention of blood clotting due to sepsis and cancer. The compound is a proprietary form of anti-thrombin III.
¿ Neurobiological Technologies Inc., of Richmond, Calif., received a second milestone payment from Merz & Co., of Frankfurt, Germany, for NTI¿s delivery of Memantine, a neuroprotective for treatment of Alzheimer¿s disease. NTI has received, over the last six months, payments totaling $5 million related to Memantine, the most widely used dementia drug in Germany.
¿ Panacos Pharmaceuticals Inc., of Gaithersburg, Md., received a $867,000 Phase II Small Business Innovation Research grant from the National Institutes of Health. The award from the National Institute of Allergy and Infectious Diseases is to fund preclinical development of Panacos¿ lead HIV drug candidate, PA-344, an HIV replication inhibitor.
¿ Protein Polymer Technologies Inc., of San Diego, said its partner, Femcare Ltd., of Nottingham, UK, received clearance to initiate clinical trials in the UK of PPTI¿s urethral bulking agent for treatment of female stress urinary incontinence. The trials are scheduled to begin in weeks.
¿ Rigel Pharmaceuticals Inc., of South San Francisco, said research published in the journal Chemistry & Biology indicates that the company¿s proprietary intracellular peptide libraries can cause functional changes in human disease cells. Each of Rigel¿s peptide4 libraries has a different structural basis.
¿ Scios Inc., of Sunnyvale, Calif., said data from a Phase Ib trial indicated that SCIO-469, its oral p38 kinase inhibitor, was well tolerated in healthy volunteers over a two-week dosing period. The objective of the randomized, double-blind, placebo-controlled trial was to evaluate the safety and tolerability of multiple oral dosing regimens. Based on the results, a Phase II trial is scheduled to begin later this year in rheumatoid arthritis patients.
¿ StemCells Inc., of Palo Alto, Calif., sold its remaining founder¿s shares in Modex Therapeutics Ltd., of Switzerland, for total proceeds of $5.2 million. The 103,577-share sale is a response to a StemCells restructuring.
¿ The Immune Response Corp., of Carlsbad, Calif., said approximately 160.7 shares of the 200 shares of Series F convertible preferred stock issued in April 1998 have been converted into about 4.2 million shares of common stock. The balance of the outstanding 39.3 million shares of preferred stock will be redeemed for about $2.7 million. When completed, the company will have no issued and outstanding shares of preferred stock.